Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (TSE:ONC)
:ONC
ONC Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.45 - C$2.08
Previous CloseN/A
Volume89.29K
Average Volume (3M)358.98K
Market Cap
C$129.45M
Enterprise ValueC$80.90M
Total Cash (Recent Filing)C$15.30M
Total Debt (Recent Filing)C$1.00M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Nov 12, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding96,602,020
10 Day Avg. Volume376,043
30 Day Avg. Volume358,979
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$6.05Price Target Upside351.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical DataData from more than 100 patients treated with pelareorep plus chemotherapy show a two-year overall survival rate more than double the historical benchmark for chemotherapy alone.
Intellectual PropertyThe company expects to extend intellectual property protection for pelareorep by up to 20 years, which would strengthen its position in the market.
Regulatory PathwayOncolytics Biotech is leveraging its Fast Track and Orphan Drug designations to accelerate consultation with the FDA and EMA regulators, aiming for an efficient regulatory path forward for its lead program.
Bears Say
Financial PositionCash position: Approx. C$14.6MN in cash and equivalents as of June 30, 2025, with management expecting cash runway into 1Q26.
Stock Exchange DelistingThe company announced it will voluntarily delist its common shares from the Toronto Stock Exchange while maintaining its Nasdaq listing, due to its US focus and investor base.
Oncolytics Biotech News
ONC FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was C$0.45 and its highest was C$2.08 in the past 12 months.
What is Oncolytics Biotech’s market cap?
Oncolytics Biotech’s market cap is C$129.45M.
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is Nov 12, 2025 which is in 88 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on Aug 08, 2025. The company reported -C$0.07 earnings per share for the quarter, beating the consensus estimate of -C$0.101 by C$0.031.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate is -0.09.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 96,602,020 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -C$0.07 in its last earnings report, beating expectations of -C$0.101. Following the earnings report the stock price went down -6.349%.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in TSE:ONC
Oncolytics Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$6.05 (351.71% Upside)
C$6.05 (351.71% Upside)
Insider Transactions
Bought Shares
Worth $150.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 12.3%
Last 30 Days ▲ 12.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.08%
12-Months-Change
Fundamentals
Return on Equity
-244.84%
Trailing 12-Months
Asset Growth
-37.54%
Trailing 12-Months
Company Description
Oncolytics Biotech
Oncolytics Biotech Inc. is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. Operating primarily in the biopharmaceutical sector, the company is committed to advancing its proprietary oncology platform, which includes its lead product candidate, pelareorep. Pelareorep is an intravenously delivered immuno-oncolytic virus designed to selectively target and destroy cancer cells while stimulating the immune system's anti-tumor response. Oncolytics Biotech aims to enhance the effectiveness of a broad range of cancer treatments through strategic collaborations and cutting-edge research.
ONC Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials, especially in breast and pancreatic cancers, and a solid financial position with new capital access. However, the ongoing search for a new CEO and a decrease in R&D spending present challenges. The overall sentiment is cautiously optimistic with key strategic advancements underway.View all TSE:ONC earnings summariesONC Stock 12 Month Forecast
Average Price Target
C$6.05
▲(351.71% Upside)
Technical Analysis
Helix BioPharma
―
Medicenna Therapeutics Corp
―
Covalon Technologies
―
BriaCell Therapeutics
―
Sernova
―
Ownership Overview
1.72% Insiders
0.07%
Mutual Funds
0.17% Other Institutional Investors
98.04% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---